According to previous studies, anti-B-cell maturation antigen (BCMA) CAR-T in MM has achieved CR rates higher than 80%, but the efficacy of BCMA CAR-T in MM CNS patients has not been reported yet (15–19). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.